TITLE

Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome

AUTHOR(S)
Baumhäkel, M; Schlimmer, N; Böhm, M
PUB. DATE
September 2008
SOURCE
International Journal of Impotence Research;Sep/Oct2008, Vol. 20 Issue 5, p493
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pathogenesis of erectile dysfunction (ED) is related to endothelial dysfunction and therefore associated with cardiovascular risk factors. Patients with a combination of risk factors, as in metabolic syndrome, are thus likely to have an increased risk of developing endothelial and ED. The angiotensin receptor antagonist irbesartan has been shown to improve endothelial function in cardiovascular high-risk patients, which suggests a beneficial effect of treatment with irbesartan on ED. The aim of the present study was to determine the influence of irbesartan on ED in patients with a metabolic syndrome. A total of 1069 consecutive hypertensive patients with a metabolic syndrome from the Documentation of hypertension and metabolic syndrome in patients with Irbesartan Treatment survey were included. Patients were treated with irbesartan or the combination of irbesartan/hydrochlorothiazide for 6 months. ED was assessed using the international index of erectile function. The Cologne Evaluation Questionnaire of Erectile Dysfunction served as a control. Erectile function increased significantly (P<0.0001) after 6 months of treatment with irbesartan, irrespective of dosage and independent of additional treatment with hydrochlorothiazide. Prevalence of ED declined to 63.7% from 78.5% at baseline, along with a significant increase in orgasmic function (P<0.001) and intercourse satisfaction (P<0.001). Treatment with irbesartan alone, as well as in combination with hydrochlorothiazide is associated with an improvement of sexual desire, frequency of sexual contacts and erectile function in hypertensive patients with the metabolic syndrome. These results suggest a beneficial role of angiotensin receptor antagonists in the treatment of metabolic syndrome, and ED.International Journal of Impotence Research (2008) 20, 493–500; doi:10.1038/ijir.2008.28; published online 3 July 2008
ACCESSION #
34251496

 

Related Articles

  • ACE-Induced Cough Less Frequently with New AII Anatgonist.  // Kidney;Jan/Feb98, Vol. 7 Issue 1, p39 

    Investigates the incidence of cough with the angiotensin II receptor antagonist valsatran in comparison with lisinopril and hydrochlorothiazide. Rate of development of persistent cough with valsatran versus lisinopril; Differences in reduction of blood pressure and cough suppression observed...

  • Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension: A Double-Blind, Placebo-Controlled, Dose-Titration Study. Guthrie, R.; Saini, R.; Herman, T.; Pleskow, W.; Sprecher, D.; Collins, G. // Clinical Drug Investigation;1998, Vol. 15 Issue 3, p217 

    This study compared the efficacy and tolerability of two dose-titrated regimens of irbesartan, an angiotensin II receptor antagonist selective for the AT subtype, vs placebo in hypertensive patients when titrated to clinical response. Patients with seated diastolic blood pressure (SeDBP) 95 to...

  • Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Fujimoto, Sohachi; Satoh, Minoru; Nagasu, Hajime; Horike, Hideyuki; Sasaki, Tamaki; Kashihara, Naoki // Nephrology Dialysis Transplantation;Dec2009, Vol. 24 Issue 12, p3651 

    Background. Hypoxia-induced tubulointerstitial injury caused by loss of peritubular capillary (PTC) blood flow may be associated with progressive renal disease. Therefore, the maintenance of blood flow in PTCs may protect against loss of renal function. A long-acting calcium channel blocker,...

  • Chapter 2: CARDIOVASCULAR DISEASE: 2F: Hypertension.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, p31 

    The article offers brief information on several drugs for hypertension including the Accupril from the firm Pfizer, the Atacand HCT from the firm AstraZeneca, the Avalide from the firm Sanofi Aventis.

  • Safety of new medicines in young children. Choonara, Imti // Archives of Disease in Childhood;Sep2011, Vol. 96 Issue 9, p872 

    The author reflects on a report which highlights the safety concerns regarding the use of angiotensin II receptor blockers in preschool children. He states that new medicines can result in a significant improvement in reducing mortality and morbidity but one has to be aware that the safety...

  • Clinical shorts.  // CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, p824 

    The article presents abstracts on medical topics which include a study of selective serotonin reuptake inhibitors as drug treatment for generalized anxiety disorder, the role of olmesartan in the prevention or delay of microalbuminuria occurrence, and research on irbesartan in patients with...

  • Angiotensin II inhibitor facilitates epidermal wound regeneration in diabetic mice. Kamber, Maria; Papalazarou, Vasileios; Rouni, Georgia; Papageorgopoulou, Evagelia; Papalois, Apostolos; Kostourou, Vassiliki // Frontiers in Physiology;Jun2015, Vol. 6, p1 

    Tissue regeneration and wound healing are severely impaired in diabetes and are associated with poor circulation and dysfunctional blood vessels. Angiotensin II inhibitors are anti-hypertensive drugs used in clinical practice to regulate blood pressure and could affect tissue remodeling. We...

  • A PILOT STUDY ON SOLUBLE (PRO)RENIN RECEPTOR IN SYSTEMIC SCLEROSIS. Gorga, Marilena; Soare, Alina-Mihaela; Gherghe, Ana-Maria; Dobrota, Rucsandra; Mambet, Cristina; Mihai, Carina // Romanian Journal of Rheumatology;2015, Vol. 24 Issue 2, p108 

    Background. Wnt signaling is involved in fi brosis, but the mechanisms of cross-talk with other pathways, like TGF-β, are not fully understood. (Pro)renin receptor (PRR) functions as an accessory protein to a V-ATP-ase responsible for acidic pH maintenance in intracellular compartments, and...

  • New free trade agreement sparks fighting over drug pricing. Moynihan, Ray // BMJ: British Medical Journal (International Edition);1/29/2005, Vol. 330 Issue 7485, p213 

    Reports on a new free trade agreement that is sparking a fight over drug pricing. Agreement which is between Australia and the US which gives US drug companies new ways to review the Australian government's system of pricing drugs; Class of drugs at the center of the dispute which is the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics